We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

94 hedge funds and large institutions have $669M invested in Jounce Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 26 increasing their positions, 29 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,251% more call options, than puts

Call options by funds: $21.4M | Put options by funds: $1.58M

86% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 14

84% more capital invested

Capital invested by funds: $365M → $669M (+$305M)

13% more funds holding

Funds holding: 83 → 94 (+11)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

10% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 29

Holders
94
Holders Change
+11
Holders Change %
+13.25%
% of All Funds
2.15%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
26
Increased
26
Reduced
29
Closed
14
Calls
$21.4M
Puts
$1.58M
Net Calls
+$19.8M
Net Calls Change
+$20M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$11.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.63M
3
Citadel Advisors
Citadel Advisors
Florida
+$6.49M
4
RG
Redmile Group
California
+$4.48M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$4.39M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$6.31M
2
GPP
Great Point Partners
Connecticut
-$3.73M
3
PHS
PFM Health Sciences
California
-$3.63M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$3.49M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$3.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$2.31M +$34.2K +1,541 +2%
BBA
27
Baker Bros. Advisors
New York
$2.23M – – –
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$2.18M +$1.88M +84,531 +659%
AIM
29
ARK Investment Management
Florida
$2.08M +$887K +39,967 +75%
Acadian Asset Management
30
Acadian Asset Management
Massachusetts
$1.94M -$3.49M -157,054 -64%
CAM
31
Cormorant Asset Management
Massachusetts
$1.85M -$6.31M -284,235 -77%
First Manhattan
32
First Manhattan
New York
$1.74M – – –
Goldman Sachs
33
Goldman Sachs
New York
$1.72M +$333K +14,993 +24%
Barclays
34
Barclays
United Kingdom
$1.65M +$1.53M +68,888 +1,407%
SIM
35
Spark Investment Management
New York
$1.35M -$2M -90,100 -60%
VEA
36
Virtus ETF Advisers
New York
$1.32M +$708K +31,919 +118%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$1.09M +$61.1K +2,751 +6%
ARTA
38
A.R.T. Advisors
New York
$1.02M +$1.02M +45,779 New
AA
39
ALPS Advisors
Colorado
$964K +$166K +7,497 +21%
TAM
40
Tocqueville Asset Management
New York
$960K – – –
Charles Schwab
41
Charles Schwab
California
$891K -$59.5K -2,681 -6%
USAA
42
United Services Automobile Association
Texas
$872K +$42.3K +1,907 +5%
JC
43
JBF Capital
Colorado
$852K +$846K +38,100 New
Morgan Stanley
44
Morgan Stanley
New York
$849K -$215K -9,683 -20%
Wells Fargo
45
Wells Fargo
California
$840K -$95.7K -4,312 -10%
D.E. Shaw & Co
46
D.E. Shaw & Co
New York
$690K +$685K +30,879 New
TCIM
47
TIAA CREF Investment Management
New York
$643K – – –
FWM
48
Frontier Wealth Management
Missouri
$606K +$601K +27,099 New
Deutsche Bank
49
Deutsche Bank
Germany
$585K -$143K -6,440 -20%
TA
50
Teachers Advisors
New York
$571K – – –
1
2
3 4 5

JNCE Hedge Fund Activity: Q1 2018 in Review

94 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2018, worth a combined $669M — up 84% from $365M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new JNCE positions and 14 closed out — a net gain of 12 holders — while 26 added to existing stakes and 29 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $11.6M. The largest seller was Cormorant Asset Management, cutting an estimated $6.31M.

  • 94 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2018, up from 83 in Q4 2017.
  • Funds reported $669M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2018, up 84% quarter-over-quarter.
  • 26 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2018 and 14 closed out, a net change of +12 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2018 was Avoro Capital Advisors, an estimated $11.6M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2018 was Cormorant Asset Management, an estimated $6.31M sold.

Based on aggregated 13F filings for Q1 2018.